| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1033684226 |
| P356 | DOI | 10.1186/S13046-014-0110-9 |
| P932 | PMC publication ID | 4304126 |
| P698 | PubMed publication ID | 25528067 |
| P50 | author | Peter Nygren | Q66206118 |
| Rolf Larsson | Q66206609 | ||
| Mahteme Haile Workneh | Q87885626 | ||
| P2093 | author name string | Magnus Sundbom | |
| Bo Hultman | |||
| Martin Ljungman | |||
| P2860 | cites work | Chemotherapy sensitivity and resistance testing: to be "standard" or to be individualized, that is the question | Q36503388 |
| Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma | Q36822182 | ||
| Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma | Q37134006 | ||
| FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. | Q37362737 | ||
| A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma | Q39860629 | ||
| Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study | Q39928697 | ||
| The fluorometric microculture cytotoxicity assay | Q39949051 | ||
| Cancer of the stomach: a review of two hospitals in Korea and Japan | Q40715208 | ||
| Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial | Q42915836 | ||
| Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery | Q43288249 | ||
| Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients | Q43421690 | ||
| Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia | Q44523391 | ||
| Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis | Q45730190 | ||
| Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie | Q46694609 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction | Q28215716 | ||
| Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer | Q29619394 | ||
| Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study | Q29619653 | ||
| Individualized tumor response testing for prediction of response to Paclitaxel and Cisplatin chemotherapy in patients with advanced gastric cancer | Q33807207 | ||
| Cancer-associated fibroblasts are positively correlated with metastatic potential of human gastric cancers | Q33942225 | ||
| Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group | Q34511070 | ||
| Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. | Q34590731 | ||
| Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials | Q34658004 | ||
| Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas - PRODIGE 19 - FFCD1103 - ADCI002. | Q34768119 | ||
| Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial | Q34928467 | ||
| Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer | Q35069652 | ||
| Prognostic value of RKIP and p-ERK in gastric cancer | Q35956840 | ||
| Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer. | Q51512560 | ||
| Detection and prognosis of recurrent gastric cancer--is routine follow-up after gastrectomy worthwhile? | Q52967914 | ||
| Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. | Q53286355 | ||
| Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. | Q53384216 | ||
| Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992. | Q53388029 | ||
| Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. | Q53604465 | ||
| Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients | Q72788080 | ||
| In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA) | Q73899272 | ||
| In vitro chemosensitivity test to predict chemosensitivity for paclitaxel, using human gastric carcinoma tissues | Q79443183 | ||
| Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy | Q83903423 | ||
| An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer | Q84077312 | ||
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial | Q84078596 | ||
| Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment | Q84248314 | ||
| Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer | Q85026066 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 110 | |
| P577 | publication date | 2014-12-21 | |
| P1433 | published in | Journal of Experimental & Clinical Cancer Research | Q13739415 |
| P1476 | title | Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy | |
| P478 | volume | 33 |
| Q57116856 | Establishment and Characterization of gc-006-03, a Novel Human Signet Ring Cell Gastric Cancer Cell Line Derived from Metastatic Ascites |
| Q51671698 | HER2 Status in Gastric Cancer: Comparison between Primary and Distant Metastatic Disease. |
| Q90485705 | Prognostic significance of poorly cohesive gastric carcinoma in Tunisian patients |
| Q26777538 | Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge |
| Q64085978 | State of the art for gastric signet ring cell carcinoma: from classification, prognosis, and genomic characteristics to specified treatments |
Search more.